2012, Number 1
Next >>
Rev Med Inst Mex Seguro Soc 2012; 50 (1)
The treatment of hypercholesterolemia is in a crossroad
Zárate A, Basurto L, Saucedo R
Language: Spanish
References: 7
Page: 1-4
PDF size: 37.82 Kb.
ABSTRACT
In order to correct the high level of cholesterol in blood is necessary to improve the life style which includes
proper nutrition and physical exercise, but frequently is added some medication. The initial medication that is
used is a stantin which decreases total cholesterol and low density cholesterol associated with increment in
high density cholesterol in order to prevent cardiovascular involvement. It is frequent the addition of other
medicaments, such as niacin or ezetemiba to achieve a greater effect on cholesterol disorders. The effectively
of anti-cholesterol elevation should be evaluated by the occurrence of cardiovascular events, instead of
the improvement in biochemist markers
REFERENCES
Shanes JG, Minadeo KN, Moret A, Groner M, Tabaie SA. Statin therapy in heart failure: prognostic effects and potential mechanism. Am Heart J 2007;254:617-623.
Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults. Ann Intern Med 2004;141 (6):413-420.
Zárate A, Basurto L, Saucedo R. Akira Endo descubridor de las estatinas recibe Premio Lasker por el beneficio sobre la enfermedad cardiovascular. Rev Med IMSS 2009; 47(2):119-120.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analyses of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
Davery SG, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304; 431-434.
Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 2009;70:815-828.
Nicholls SJ, Brewer HB, Kastelin JP, Krueger KA, Wang MD, Shao M,et al. Effects of the CETP inhibitor evacetrapib administered monotherapy or in combination with statins on HDL and LDL cholesterol. JAMA 2011;306: 2099-2109.
Full text